Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:CSL_Limited
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:focusesOn |
nephrology
iron deficiency cardio-renal therapies |
| gptkbp:formerName |
gptkb:Galenica
|
| gptkbp:founded |
1872
|
| gptkbp:headquartersLocation |
gptkb:Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vifor Pharma
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:keyPerson |
gptkb:Abbas_Hussain
|
| gptkbp:listedOn |
SIX Swiss Exchange (until 2022)
|
| gptkbp:mergedInto |
gptkb:CSL_Vifor
|
| gptkbp:numberOfEmployees |
~2500
|
| gptkbp:parentCompany |
gptkb:CSL_Limited
|
| gptkbp:product |
gptkb:Mircera
gptkb:Ferinject gptkb:Velphoro gptkb:Venofer |
| gptkbp:publiclyTraded |
no
|
| gptkbp:website |
https://www.viforpharma.com/
|
| gptkbp:bfsParent |
gptkb:CSL_Limited
gptkb:PhRMA |
| gptkbp:bfsLayer |
6
|